Clinical Trials Logo

Marijuana Abuse clinical trials

View clinical trials related to Marijuana Abuse.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06171399 Completed - Cannabis Use Clinical Trials

Cannabis Edibles Packaging Descriptors Experiment

Start date: March 15, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to assess differences in perceptions of product appeal, harm, and subsequent willingness to try cannabis edibles products with/without product descriptors of interest.

NCT ID: NCT05939466 Completed - Fibromyalgia Clinical Trials

Medical Cannabis for Treating Pain Related to Fibromyalgia

Bedrocan®-LD
Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The goal of this interventional study is to learn about the effect of Medicinal Cannabis (Bedrocan®) on Fibromyalgia patients with pain resistant to conventional therapy. The main question the trial aims to answer are: - Is Bedrocan® effective for treating fibromyalgia-related pain in patients resistant to conventional therapy? - Can a low dosage of medical cannabis taken as a decoction reduce fibromyalgic pain? All patients were trained on how to make the decoction: therapy was started with 100 mg/day (1 folder) and increased to 200 mg/day (2 folders) in non-responders.

NCT ID: NCT05566730 Completed - Cannabis Use Clinical Trials

Culturally Tailored Cannabis Use Disorder App

Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The present study aims to address disparities in cannabis use outcomes among African American/Black (hereby referred to as Black) adults with cannabis use disorder (CUD). The specific aims of this study are: (1) to develop a culturally adapted, mobile app for Black cannabis users (CT-MICART) using knowledge from the current research team, published literature, expert opinion, and feedback from the Community Research Advisory Board (CRAB), (2) to pilot test CT-MICART and (3) focus on analysis of data collected as part of Aim 2.

NCT ID: NCT05554926 Completed - Marijuana Abuse Clinical Trials

Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects

Start date: December 16, 2022
Phase: Phase 1
Study type: Interventional

Cannabis use is increasing and will only further escalate with legalization of recreational and medical cannabis use in western countries , with a prevalence greater than 30 % in the US and most European countries for individuals between 16 and 24 years of age. Approximately 9 % of those who use cannabis will become addicted. The number goes up to about 1 in 6 among those who start using cannabis as teenagers and to 25 to 50 % among those who smoke cannabis daily. The consequences of cannabis abuse in the most prone population (14-25 years of age) are extremely serious, and may include addiction, altered brain development, poorer educational outcomes, cognitive impairment, lower income, greater welfare dependence, unemployment and lower relationship and life satisfaction. There are no available pharmacological treatments of cannabis use disorder (CUD). Thus, the development of safe and effective medications for the treatment of CUD is an urgent public health priority. The preclinical efficacy and available ADMET (Administration, Distribution, Metabolism, Elimination and Toxicology) in animal and human data suggest that AEF0117, an investigational new study drug, could constitute a very efficacious and safe treatment for cannabis abuse disorders. The purpose of this research is to study how AEF0117 influences the subjective effects of cannabis in subjects with CUD. AEF0117 acts in the same parts of the brain as THC (tetrahydrocannabinol), the active ingredient of marijuana, and may temporarily alter some of cannabis's effects. This will be a Phase 1, open-label, nonrandomized, single-dose study in healthy male subjects. Potential subjects will be screened to assess their eligibility to enter the study within 28 days prior to the dose administration. Subjects will be admitted into the study site on Day 1. On the morning of Day 1, all subjects will receive a single oral dose of 2 mg containing approximately 100 μCi of [4-14C]AEF0117 approximately 1 hour after completion of a low fat breakfast.

NCT ID: NCT05554146 Completed - HIV Infections Clinical Trials

Pain Inflammation and Cannabis in HIV

PITCH-E
Start date: October 28, 2022
Phase: N/A
Study type: Interventional

This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. The investigators will observe how varying ratios of THC (tetrahydrocannabinol) and CBD (cannabidiol) in medical cannabis impact neuropathic pain, inflammation and adverse events.

NCT ID: NCT05494437 Completed - Cannabis Withdrawal Clinical Trials

Effect of PP-01 on Cannabis Withdrawal Syndrome

Start date: October 27, 2022
Phase: Phase 2
Study type: Interventional

This study will be a randomized, double-blind, placebo-controlled, multicenter trial conducted to evaluate whether PP-01 mitigates the withdrawal symptoms associated with discontinuing cannabis in participants with moderate to severe Cannabis Use Disorder (CUD). The study will enroll approximately 225 participants with moderate to severe CUD and will include 5 arms, including a placebo arm, to help assess the incidence and severity of withdrawal symptoms in heavy long-term users of cannabis. Participants receive study medication for 34 days and participate in 11 visits (7 at a clinic and 4 telemedicine).

NCT ID: NCT05407285 Completed - Cannabis Clinical Trials

A Study of Ingested Cannabidiol in Healthy Occasional Cannabis Users

Start date: July 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purposes of this study are 1) to determine if the administration of different low doses of oral CBD (20 mg, 50 mg, 100 mg and 200 mg) result in detectable subjective pleasant drug effect compared to placebo and 2) to qualitatively explore whether low dose of oral CBD is associated with effects that are not detected with the available research tools.

NCT ID: NCT05382273 Completed - Cannabis Use Clinical Trials

Cannabis Tolerance Break Resource Study: T-Break Guide

Start date: April 22, 2021
Phase:
Study type: Observational

The purpose of this pilot study is to conduct research into the value of using the T-Break Guide for assisting people taking a tolerance break from cannabis. The hope is that this initial research will yield some insights and benchmarks into the Guide's efficacy, and provide a foundation for a later randomized control study. The following are some key research questions: 1. How did participants use the Guide? (Eg: daily; read once; 'a la carte') 2. How did using the Guide increase fidelity to tolerance break (starting, continuing, completing a break)? 3. Did using the Guide yield any benefits beyond tolerance break fidelity? (Eg: insight into patterns of use)

NCT ID: NCT05328362 Completed - Cannabis Use Clinical Trials

CanCope: Digital Intervention for Coping With Cannabis Craving

Start date: August 27, 2021
Phase: N/A
Study type: Interventional

The CanCope Study is a micro-randomized trial conducted to gather evidence about and compare the effectiveness of a momentary intervention to help young adults cope with cannabis cravings as they attempt to reduce their use.

NCT ID: NCT05192239 Completed - Endurance Exercise Clinical Trials

Influence of Edible Marijuana on Endurance Exercise Performance

Start date: December 9, 2021
Phase: Early Phase 1
Study type: Interventional

Lots of people, including athletes and people who like to exercise regularly, enjoy marijuana. Some people believe marijuana might improve their ability to exercise. There are no recent, up-to-date scientific studies to suggest that this belief is right or wrong. The goal of this study is to determine the influence of marijuana on exercise performance.